EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Graphite Bio's enterprise value is $1,112.46 Mil.
Graphite Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-70.70 Mil. Therefore, Graphite Bio's EV-to-EBITDA for today is -15.73.
The historical rank and industry rank for Graphite Bio's EV-to-EBITDA or its related term are showing as below:
GRPH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -86.63 Med: 0 Max: 3.42
Current: -15.73
During the past 5 years, the highest EV-to-EBITDA of Graphite Bio was 3.42. The lowest was -86.63. And the median was 0.00.
GRPH's EV-to-EBITDA is ranked worse than 100% of 465
companies
in the Biotechnology industry
Industry Median: 9.34
vs GRPH: -15.73
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Graphite Bio EV-to-EBITDA Historical Data
The historical data trend for Graphite Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Graphite Bio's EV-to-EBITDA
For the Biotechnology subindustry, Graphite Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Graphite Bio's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Graphite Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Graphite Bio's EV-to-EBITDA falls into.
Graphite Bio EV-to-EBITDA Calculation
Graphite Bio's EV-to-EBITDA for today is calculated as:
Graphite Bio's current Enterprise Value is $1,112.46 Mil.
Graphite Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Graphite Bio (NAS:GRPH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Graphite Bio's PE Ratio for today is calculated as:
Graphite Bio's share price for today is $3.18.
Graphite Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Graphite Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRPH has been successfully added to your 